Recently, Forbes officially released the 2020 Forbes Asia "30 Under 30" list.
Forbes 30 Under 30 Asia,"30U30"
This is the fifth year that Forbes Asia has released this list. The list selected 300 young talents from the Asia-Pacific region from over 3,500 nominations. They are technological disruptors and innovators. Zhang Shengming, founder and CEO of Beijing Jianyi Bao Technology Co., Ltd., a portfolio company of China Zhongji Investment, successfully entered the Healthcare & Science list. This marks Zhang Shengming's second appearance on a Forbes list, following his inclusion in the 2019 Forbes China "30U30" list.
Also included in the list are Ashleigh Barty, the world's number one ranked Australian female tennis player; the South Korean pop music group Twice; Park So-dam, a South Korean actress who appeared in the Oscar-winning film "Parasite"; and Juju Noda, a 14-year-old Japanese racing prodigy.
Zhang Shengming's profile on the Forbes website
It is reported that the 2020 Forbes Asia selection process invited many famous industrial and commercial leaders and entrepreneurs to serve as judges, including Hiroshi Mikitani, CEO of Rakuten; C Vijayakumar, HCL Corporation Executive Director and CEO; Kai-Fu Lee, CEO of Sinovation Ventures; Allan Zeman, founder and chairman of Lan Kwai Fong; and Fang Aizhi, CEO of ZhenFund. They reviewed 3,500 candidates from across the Asia-Pacific region, including China, Australia, Japan, South Korea, and India. The selection criteria included whether the candidates demonstrated leadership, influence, and potential for success, and whether they reflected the entrepreneurial spirit upheld by Forbes. After multiple rounds of rigorous selection, 300 outstanding young talents representing Asia were finally selected from ten fields: Enterprise Technology, Consumer Technology, Finance and Venture Capital, Art, Entertainment and Sports, and Healthcare & Science.
In 2013, Zhang Shengming, a graduate of Tianjin Medical University, joined a well-known foreign pharmaceutical company and insurance company, working in the market development of innovative drugs. He led the development and implementation of the first domestic pharmaceutical and insurance company cooperation project, becoming one of the earliest industry experts in systematically developing insurance products for people with pre-existing conditions. Through continuous innovation and practice, Zhang Shengming deeply understood the "cross-border pain" of the Greater Health industry, and also deeply understood the lack of risk protection and health management among a large number of people with pre-existing conditions and the resulting life difficulties, so he made up his mind to take root in this field.
In 2017, Zhang Shengming founded Beijing Jianyi Bao Technology Co., Ltd. As the first domestic comprehensive service platform systematically engaged in risk and health management for people with pre-existing conditions, Jianyi Bao successfully connected pharmaceutical companies, medication scenarios, and financial insurance companies. Addressing the cross-border pain points of the three parties, Jianyi Bao, with its professional, technological, and innovative core capabilities, has cooperated with insurance companies to develop insurable insurance products for people with pre-existing conditions, solving their health insurance problems.
Since its establishment, Jianyi Bao has successively launched the "Xin Yi Bao" chronic disease comprehensive protection plan and You Jia Ai long-term anti-cancer insurance (post-operative insurable for thyroid cancer patients), among other commercial insurances targeting specific patients, achieving several industry firsts. The products cover more than ten medical specialties, including hypertension, diabetes, hyperlipidemia, rare diseases, tumors, and respiratory diseases, improving the situation of hundreds of thousands of patients who have been impoverished or have fallen back into poverty due to illness, bringing new hope to their lives.
Jianyi Bao's mature business model has, in less than two years, received multiple rounds of investment from Puhua Capital, Baidu Venture Capital, China Zhongji Investment, and Weilai Capital. At the same time, Jianyi Bao has also been widely reported by authoritative media such as People's Daily Online, Xinhua Net, China Insurance News, and the 21st Century Business Herald.
In 2019, Zhang Shengming was invited to be interviewed for the People's Daily Online's 2019 Two Sessions special coverage, and in October of the same year, he was selected for the 2019 Forbes China 30 Under 30 list.
Zhang Shengming's interview with People's Daily Online in 2019
Regarding his inclusion in the 2020 Forbes Asia 30U30 list, Zhang Shengming expressed his great honor and gratitude to Forbes for its recognition of Jianyi Bao and its model. In the future, Jianyi Bao will continue to focus on the health insurance innovation field centered on insurance for those with pre-existing conditions, and develop and launch more commercial insurance products targeted at specific groups.
Jianyi Bao Established in 2017, as a new generation of medical security solution platform for people with pre-existing conditions, Jianyi Bao connects pharmaceutical companies, medical channels, and financial insurance companies, developing innovative insurance products targeting the cross-border pain points of the three parties to solve the health insurance problems of people with pre-existing conditions, building a comprehensive insurance service platform for 450 million people with pre-existing conditions.
In December 2019, China Zhongji Investment completed its investment in Jianyi Bao. This is another layout of China Zhongji Investment in the Greater Health field, following Daying Technology, Zhesheng Technology, Wuwei Kang, and United Imaging Healthcare. China Zhongji Investment will continue to focus on outstanding companies in the medical field and promote the innovative development of the Greater Health industry.
